Trupanion (TRUP) Receives a Buy from Guggenheim

By Jason Carr

Guggenheim analyst David Westenberg maintained a Buy rating on Trupanion (TRUPResearch Report) today and set a price target of $36.00. The company’s shares closed last Monday at $33.00.

Westenberg has an average return of 3.2% when recommending Trupanion.

According to TipRanks.com, Westenberg is ranked #1690 out of 5679 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trupanion with a $33.75 average price target, a 5.2% upside from current levels. In a report issued on November 6, Northland Securities also maintained a Buy rating on the stock with a $40.00 price target.

See today’s analyst top recommended stocks >>

Based on Trupanion’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $782K. In comparison, last year the company had a net profit of $1.21 million.

Based on the recent corporate insider activity of 91 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRUP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trupanion, Inc. engages in the provision of medical insurance for cats and dogs. It operates through the following two segments: Subscription Business and Other Business. The Subscription Business segment involves in the monthly subscriptions of pet medical insurance.